International Stem Cell Corp
OTC:ISCO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
International Stem Cell Corp
Gross Profit
International Stem Cell Corp
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
International Stem Cell Corp
OTC:ISCO
|
Gross Profit
$5.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$43.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$23.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$27.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$10.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
27%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$12.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
International Stem Cell Corp
Glance View
International Stem Cell Corp. operates as a clinical stage biotechnology company. The company is headquartered in Carlsbad, California. The company went IPO on 2006-09-25. The firm is focused on therapeutic and biomedical product development. The firm's segments include therapeutic market, anti-aging market and biomedical market. The firm is primarily a research and development company, for the therapeutic market, which is focused on clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The firm's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC) that develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.
See Also
What is International Stem Cell Corp's Gross Profit?
Gross Profit
5.1m
USD
Based on the financial report for Dec 31, 2025, International Stem Cell Corp's Gross Profit amounts to 5.1m USD.
What is International Stem Cell Corp's Gross Profit growth rate?
Gross Profit CAGR 10Y
-1%
Over the last year, the Gross Profit growth was -5%. The average annual Gross Profit growth rates for International Stem Cell Corp have been 1% over the past three years , 3% over the past five years , and -1% over the past ten years .
